A new lung cancer therapy is believed to double the life expectancy of patients after trials have shown that it can successfully stop cancer cells from hiding from the body’s own defences – meaning the cancer is attacked and killed by the body’s own immune system.
Nivolumab was tested on 582 people, and the results were described as a “milestone” in cancer therapy treatments. Unlike other forms of cancer treatments, Nivolumab encourages the body’s natural defences to fight the cancer.
BBC News reports:
Lung cancer is the most deadly type of cancer, killing nearly 1.6 million people every year.
It is hard to treat as it is often diagnosed late and many people with smoking-related diseases are unsuitable for surgery.
Your immune system is trained to fight infection, but it also attacks parts of the body if they malfunction – such as in cancers.
However, tumours have a few tricks up their sleeve in order to survive.
They can produce a protein called PD-L1 which switches off any part of the immune system that tries to attack them.
Nivolumab is one of a suite of drugs called “checkpoint inhibitors” being developed by pharmaceutical companies.
They stop cancers turning off the immune system so the body can keep on attacking the tumour.
The trial, conducted in Europe and the US, was on patients who had advanced lung cancer and who had already tried other treatments.
People on standard therapy lived for another 9.4 months at this stage, but those taking Nivolumab lived for 12.2 months on average.
However, some patients did spectacularly well. Those whose tumours were producing high levels of PD-L1 lived for another 19.4 months.
The data was presented by the pharmaceutical company Bristol-Myers Squibb.
Lead researcher Dr Luis Paz-Ares, from the Hospital Universitario Doce de Octubre in Madrid, Spain, said: “[The results] mark a milestone in the development of new treatment options for lung cancer.”
“Nivolumab is the first PD-1 inhibitor to show a significant improvement in overall survival in a phase III trial in non-squamous non-small cell lung cancer.”
Many other companies are assessing similar drugs.
Dr Martin Forster, from the University College London Cancer Institute, is trialling some of them.
He told the BBC News website: “It’s really exciting, I think these drugs will be a paradigm shift in how we treat lung cancer.”
He said that after chemotherapy failed, current survival rates were “dire”.
“But in those that respond [to immunotherapy] there seems to be very prolonged disease control, I think it’s a huge shift in lung cancer and for patients it’s going to be dramatic,” he said.
Cancer Research UK said harnessing the immune system would be an “essential part” of cancer treatment.
Dr Alan Worsley, the charity’s senior science information officer, told the BBC: “This trial shows that blocking lung cancer’s ability to hide from immune cells may be better than current chemotherapy treatments.”
“Advances like these are giving real hope for lung cancer patients, who have until now had very few options.”
It is hoped these drugs will work in a range of cancers. Nivolumab has already been approved in the US for melanoma.
But there are still big questions to be answered.
The long-term consequences of modifying the immune system are still unknown and the best way of figuring out who will respond to therapy is uncertain.
And these therapies are also likely to be very expensive and so will pose a challenge for health services trying to offer them.